Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection

Virology
Rong XuLeonidas Stamatatos

Abstract

Immunization by the SF162gp140 or the DeltaV2gp140 HIV-1 envelope proteins results in the generation of strong homologous neutralizing antibodies (NAbs) that offer similar degree of protection from disease-development to macaques challenged with homologous virus. These two immunogens elicit weak cross-reactive NAbs and their effectiveness against heterologous challenge is currently unknown. To examine this issue, we immunized macaques with SIVGag p55 and either the SF162gp140 or the DeltaV2gp140 and challenged them intravenously with SHIV-89.6P. All animals became infected but previous immunization with SF162gp140 accelerated the development of anti-SHIV89.6P neutralizing antibody responses following infection. DeltaV2gp140 is derived from SF162gp140 following the deletion of 30 amino acids and one N-linked glycosylation site from the V2 loop. Our results suggest that even small differences in HIV Envelope immunogen structure can affect the neutralizing antibody responses generated following infection.

References

Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·P A LuciwC Cheng-Mayer
Apr 3, 2001·Science·D Paydarfar, W J Schwartz
Mar 5, 2002·Nature Medicine·Mark B Feinberg, John P Moore
Mar 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Douglas D RichmanChristos J Petropoulos

❮ Previous
Next ❯

Citations

Oct 29, 2014·Proceedings of the National Academy of Sciences of the United States of America·George K LewisRobert C Gallo
Apr 14, 2011·The Journal of Biological Chemistry·Grégoire MartinLoïc Martin
Mar 3, 2010·Annual Review of Immunology·John R Mascola, David C Montefiori
Aug 23, 2011·Expert Review of Vaccines·Rogier W Sanders
Nov 5, 2008·Expert Review of Vaccines·Sean P McBurney, Ted M Ross
Nov 5, 2008·Expert Review of Vaccines·Silvia BaroncelliAndrea Cara
Feb 10, 2009·Journal of Medical Primatology·Patricia PolacinoShiu-Lok Hu
Jun 19, 2013·Immunological Reviews·John R Mascola, Barton F Haynes
Nov 7, 2006·AIDS·Josef Vlasak, Ruth M Ruprecht
Feb 21, 2008·AIDS Research and Human Retroviruses·Suganya SelvarajahDennis R Burton
Dec 14, 2011·Current Opinion in HIV and AIDS·Marc P Girard, Stanley A Plotkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.